A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Biliary tract disorders; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
- Focus Therapeutic Use
- 19 Oct 2016 Status changed from not yet recruiting to recruiting.
- 16 Jul 2016 Status changed from recruiting to not yet recruiting.
- 12 Jul 2016 New trial record